Latrunculin A
Cat.No:IL1980 Solarbio
CAS:76343-93-6
Storage:Store at -20℃,2 years
Purity:≥98%
Appearance:A Solution in Ethanol(See label for concentration)
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Cytoskeleton >
Latrunculin ACAS:76343-93-6
Storage:Store at -20℃,2 years
Purity:≥98%
Appearance:A Solution in Ethanol(See label for concentration)
Qty:
Size:
CAS | 76343-93-6 |
Name | Latrunculin A |
Molecular Formula | C22H31NO5S |
Molecular Weight | 421.55 |
Purity | ≥98% |
Appearance | A Solution in Ethanol(See label for concentration) |
Storage | Store at -20℃,2 years |
MDL | MFCD27977552 |
SMILES | CC1CCC2CC(CC(O2)(C3CSC(=O)N3)O)OC(=O)C=C(CCC=CC=C1)C |
InChIKey | DDVBPZROPPMBLW-IZGXTMSKSA-N |
InChI | InChI=1S/C22H31NO5S/c1-15-7-5-3-4-6-8-16(2)11-20(24)27-18-12-17(10-9-15)28-22(26,13-18)19-14-29-21(25)23-19/h3-5,7,11,15,17-19,26H,6,8-10,12-14H2,1-2H3,(H,23,25)/b4-3+,7-5-,16-11-/t15-,17-,18-,19+,22-/m1/s1 |
PubChem CID | 445420 |
Target Point | G-actin |
Passage | Cytoskeleton |
Background | Latrunculin A is an inhibitor. In addition, latrunculin A was able to bind to actin monomers and inhibit actin aggregation. |
Biological Activity | Latrunculin A 来自 Latrunculia magnifica,是一种 G 肌动蛋白聚合抑制剂,可与肌动蛋白单体结合,抑制肌动蛋白的聚合,对 ATP-肌动蛋白、ADP-Pi-肌动蛋白、ADP-肌动蛋白和 G-肌动蛋白的 Kds 分别为 0.1、0.4、4.7 μM 和 0.19 μM。[1-2] |
In Vitro | Latrunculin A bound ATP-actin monomers with a higher affinity(Kd = 0.1 μM)than ADP-Pi-actin(Kd = 0.4 μM)or ADP-actin(Kd = 4.7 μM). Latrunculin A binds weakly to actin filaments with a Kd >100 μM.[1] Latrunculin A and carbamates 4- 6 displayed potent anti-invasive activity against the human highly metastatic human prostate cancer PC-3M cells in a Matrigel assay at a concentration range of 50 nM to 1 microM. Latrunculin A(500 nM)decreased the disaggregation and cell migration of PC-3M-CT+ spheroids by 3-fold. Latrunculin A(IC 50 6.7 microM)suppress hypoxia-induced HIF-1 activation in T47D breast tumor cells.[3] Latrunculin A caused a dose- and time-dependent reduction in the high cytoplasmic HuR content of HepG2 and Huh7 hepatocellular carcinoma(HCC)cells.[4] Latrunculin A induced acute cell injury and programmed cell death through activating the caspase-3/7 pathway.[5] |
In Vivo | Intraperitoneal(i.p.)injection of latrunculin A significantly improved survival rate in mice without any major side-effects.[5] |
Data Literature Source | [1]. Fujiwara I,et al. Latrunculin A Accelerates Actin Filament Depolymerization in Addition to Sequestering Actin Monomers. Curr Biol. 2018 Oct 8;28(19):3183-3192.e2. [2]. Coué M,et al. Inhibition of actin polymerization by latrunculin A. FEBS Lett. 1987 Mar 23;213(2):316-8. [3]. Sayed KA,et al. Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells. J Nat Prod. 2008 Mar;71(3):396-402. [4]. Doller A,et al.. The cytoskeletal inhibitors latrunculin A and blebbistatin exert antitumorigenic properties in human hepatocellular carcinoma cells by interfering with intracellular HuR trafficking. Exp Cell Res. 2015 Jan 1;330(1):66-80. [5]. Konishi H,et al. Latrunculin a has a strong anticancer effect in a peritoneal dissemination model of human gastric cancer in mice. Anticancer Res. 2009 Jun;29(6):2091-7. |
Unit | Bottle |
Specification | 25ug |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.